Top Markets
Coin of the day
Novacyt S.A. Novacyt S.A.

Novacyt S.A.

ALNOV
주식 순위 #26272
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A.... Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
주가
$0.58121603
시가총액
$42.14M
변동 (1일)
-4.48%
변동 (1년)
6.58%
국가
FR
거래 Novacyt S.A. (ALNOV)

카테고리

Novacyt S.A. (ALNOV)의 매출
Aug 2026 기준 매출 TTM: 0
Novacyt S.A.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Novacyt S.A.의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
- -
DE